ALVIO.PA Valerio Therapeutics
- Market cap
- EUR 276M
- P/E
- -
- P/B
- 91.71x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 1.0/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALVIO.PA undervalued?
Graham numberThe Graham number of Valerio Therapeutics cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Valerio Therapeutics fundamental analysis
2 of 11 checks passedROE 0/2
The stock's ROE indicates a negative return (-70.86%) on shareholders' equity, suggesting poor financial performance.
ROA 0/2
The stock's ROA (-87.51%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.
PBV 2/2
The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.
DER 2/2
The stock has a minimal amount of debt (45%) relative to its ownership, showcasing a strong financial position and lower risk for investors.
Revenue Growth 0/2
Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.
Net Profit Growth 0/2
Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.
Assets Growth 0/2
Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.
Graham Number 0/1
Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.
Dividend Growth 0/2
The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.
Dividend 0/2
The company's lack of dividends in the past three years may concern investors seeking regular income.
Buffet Intrinsic Value 0/1
Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Valerio Therapeutics stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Valerio Therapeutics
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody" drug conjug…
Full company profileValerio Therapeutics financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Valerio Therapeutics annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.42M | 9.51M | 6.13M | 4.29M | 1.78M | 4.06M | 1.44M | 1.80M | 1.79M | 2.57M | 12.4M |
| Gross Profit | 3.77M | 8.87M | 5.91M | 3.94M | 1.43M | 3.69M | 929K | 1.27M | 1.28M | 1.73M | -428K |
| Operating Income | -23.2M | -19.2M | -15.6M | -9.79M | -8.94M | -7.33M | -17.1M | -20.3M | -16.5M | -550K | -10.1M |
| EBITDA | -19.8M | -63.9M | -946K | -11.0M | 2.34M | -5.86M | -17.1M | -19.7M | -12.1M | 542K | -7.81M |
| Net Income | -22.7M | -59.1M | -9.40M | -33.7M | 1.09M | -5.94M | -19.6M | -20.3M | -23.9M | -4.90M | -9.44M |
| EPS | -0.48 | -1.16 | -0.18 | -0.55 | 0.01 | -0.07 | -0.18 | -0.15 | -0.16 | -0.03 | -0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 125M | 78.1M | 63.3M | 37.6M | 46.5M | 53.1M | 43.1M | 35.3M | 17.9M | 15.2M | 18.1M |
| Total Liabilities | 31.0M | 28.2M | 17.8M | 20.4M | 17.5M | 20.1M | 20.8M | 20.5M | 26.2M | 13.2M | 18.3M |
| Shareholders' Equity | 94.1M | 49.9M | 45.4M | 17.2M | 29.0M | 32.9M | 22.3M | 14.8M | -8.93M | 2.08M | -233K |
| Cash & Short-term Investments | 29.2M | 14.3M | 11.3M | 5.71M | 14.5M | 17.9M | 14.6M | 6.82M | 1.18M | 1.05M | 656K |
| Total Debt | 106K | 130K | 7.04M | 8.58M | 6.26M | 9.94M | 10.1M | 9.00M | 13.4M | 7.61M | 12.8M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -17.6M | -28.3M | -11.3M | -7.70M | -4.68M | -8.57M | -9.44M | -18.6M | -12.5M | 1.84M | -2.73M |
| Capital Expenditure | 545K | 65.0K | 45.0K | 26.0K | 119K | 139K | 488K | 183K | 319K | 1.32M | 2.01M |
| Free Cash Flow | -18.2M | -28.3M | -11.3M | -7.73M | -4.80M | -8.71M | -9.93M | -18.8M | -12.8M | 521K | -4.74M |
| Ratios | |||||||||||
| ROE | -24.1% | -118.4% | -20.7% | -196.1% | 3.8% | -18.0% | -87.8% | -137.4% | - | -236.0% | - |
| ROA | -18.1% | -75.7% | -14.9% | -89.6% | 2.3% | -11.2% | -45.4% | -57.7% | -133.5% | -32.2% | -52.2% |
| Net Profit Margin | -512.5% | -621.5% | -153.4% | -786.6% | 61.3% | -146.2% | -1,355.6% | -1,130.2% | -1,334.7% | -190.4% | -76.1% |
| Debt to Equity | 0.00x | 0.00x | 0.16x | 0.50x | 0.22x | 0.30x | 0.45x | 0.61x | - | 3.67x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Valerio Therapeutics dividends
Valerio Therapeutics has not paid dividends in the last 9 fiscal years.
Last stock split: 766:761 on Mar 17, 2021.
Who owns Valerio Therapeutics
- Insiders 29.94%
- Institutions 37.45%
- Public & others 32.61%
- Shares outstanding 588M
- Free float 147M
Valerio Therapeutics company profile
- Company name
- Valerio Therapeutics
- Ticker
- ALVIO.PA
- ISIN
- FR0010095596
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 41
- Fiscal year end
- December
- Address
- 49, boulevard du GEnEral Martial Valin, Paris, France, 75015
- Phone
- 33 1 45 58 76 00
- Website
- valeriotx.com
About Valerio Therapeutics
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody" drug conjugates, and chimeric antigen receptors. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.
Valerio Therapeutics management
2- Dr. Gilles Besin Ph.D.CEO & Director
- Mr. Wael Jdey Ph.D.CTO & Director